Park Ha Biological Technology Faces Securities Fraud Class Action

NEW YORK, Sept. 10, 2026 /CourierPR/ -- Park Ha Biological Technology Co., Ltd faces legal action over alleged securities fraud. Rosen Law Firm has issued a reminder to investors who purchased securities of Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) between December 27, 2024, and July 8, 2025, inclusive, to consider joining a class action lawsuit.

The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements about the company. Specifically, the lawsuit claims that Park Ha was involved in a fraudulent stock promotion scheme that included social media-based misinformation and impersonated financial professionals. The lawsuit also alleges that the company's public statements and risk disclosures failed to mention the false rumors and artificial trading activity driving the stock price.

According to the lawsuit, Park Ha's initial public offering (IPO) was intentionally structured with an extremely low public float to facilitate the manipulation scheme. The plaintiffs argue that as a result, the company's positive statements about its business, operations, and prospects were misleading and lacked a reasonable basis.

The deadline for investors to seek appointment as a lead plaintiff is September 28, 2026. A lead plaintiff will act as a representative party on behalf of other class members in directing the litigation.

Rosen Law Firm, known for its track record in handling securities class actions, encourages investors to select qualified counsel with a history of success. The firm's website notes that it has secured billions of dollars for investors and has been ranked in the top 4 for number of settlements in securities class actions since 2013.

As of now, no class has been certified, and until then, investors are not represented by counsel unless they retain one. Investors may choose to remain as absent class members and take no action at this time.